Horizon Pharma is a biopharmaceutical company focused on the development and commercialization of innovative medicines to target unmet therapeutic needs in the areas of arthritis, pain and inflammatory diseases. The company’s strategy involves commercializing its products in the United States, exploring co-promotion for its DUEXIS novel tablet formulation (approved by the U.S. FDA in 2011), and entering into licensing or additional distribution agreements for commercialization of its products outside the United States. For more information, visit the company’s Web site at www.horizonpharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: